FogPharma (Fog Pharmaceuticals Inc.)

https://www.fogpharma.com

FogPharma's mission is to drastically reduce the burden of disease on patients and their families by inventing new types of drugs that squelch abnormal physiological processes in ways previously imagined but considered unattainable. The company is pioneering the discovery, development and commercialization of Helicon™ peptides, a new drug modality that uniquely combines the cell-permeability and oral dosing optionality of traditional small molecule drugs with the high specificity, broad target accessibility and rapid discovery arc of monoclonal antibody drugs. FogPharma was spun out of Harvard University in 2016 by pioneering academic scientist, serial life science entrepreneur, venture capitalist and successful biotech company-builder Dr. Gregory Verdine. FogPharma is headquartered in Cambridge, Mass., and has raised more than $180 million to date. *

	Start	2016-01-01 established (s-off)
	Predecessor	Harvard University
	Industry	FOG-001 (FogPharma)
	Industry 2	Helicon™ peptides
	Person	Verdine, Gregory (Greg) (LifeMine Therapeutics 202203 CEO + Co-Founder + FogPharma 201805 CEO + Founder)
	Person 2	Klausner, Richard (Rick) (Lyell Immunopharma 201910 CEO + Founder before Juno Therapeutics + NCI)

	Region	Cambridge, MA
	Country	United States (USA)
	Street	30 Acorn Park Drive Cambridge Discovery Park
	City	02140 Cambridge, MA
	Tel	+1-617-945-9510
		Address record changed: 2021-10-31

Basic data	Employees	n. a.

		* Document for »About Section«: FogPharma (Fog Pharmaceuticals Inc.). (3/1/21). "Press Release: FogPharma Announces $107 Million Series C Financing to Advance Direct ß-Catenin Antagonist and Universal Druggability Platform". Cambridge, MA.

		Record changed: 2023-07-10

Picture Berlin Partner Top News Healthtech Company Mika 650x200px

More documents for FogPharma (Fog Pharmaceuticals Inc.)

[1] FogPharma (Fog Pharmaceuticals Inc.). (3/1/21). "Press Release: FogPharma Announces $107 Million Series C Financing to Advance Direct ß-Catenin Antagonist and Universal Druggability Platform". Cambridge, MA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]